Myrna Thomas

Myrna Thomas serves as Vice President, Quality – Manufacturing at Geneos Therapeutics, overseeing quality operations to ensure compliance with global regulatory standards and supporting the advancement of the company’s personalized immunotherapy oncology platform.

She brings over 20 years of biopharmaceutical experience, with expertise in GMP manufacturing, quality systems, and regulatory compliance. Ms. Thomas has held leadership roles at Wyeth (now Pfizer), Merck, Wuxi AppTec, and Aventis Behring (now CSL), where she led quality assurance and manufacturing quality functions, supported regulatory inspections, and contributed to the development and commercialization of monoclonal antibodies and therapeutic protein programs.

Ms. Thomas has extensive experience with global regulatory agencies, including the FDA, Health Canada, TGA, ANVISA, and the Korean Ministry of Food and Drug Safety, supporting multiple submissions and inspections across clinical and commercial stages.

She holds an MS in Analytical Chemistry, a BS in Biochemistry and Biophysics, and an AAS in Mortuary Science.